Tumour-infiltrating lymphocyte therapy has shown durable responses in refractory melanoma, including a 31.4% objective response rate in phase II data. The 2024 FDA approval of Lifileucel marked a milestone as regulators in other markets continue reviews.
Researchers identify DPY30 as an epigenetic target to sensitize pancreatic tumors to immunotherapy. UC San Diego researchers redirect CMV immunity against pancreatic cancer in preclinical models. A Fred Hutch researcher receives ACS grant to study immunotherapy resistance in melanoma.
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
A Feb. 20, 2026 study in the Journal of Experimental Medicine identified CD8 T cell-derived TNF and TNFR2 signaling as drivers of ICI-related myocarditis in mice. Blocking TNFR2 prevented the inflammatory cycle in the heart.
Scientists at Cincinnati Children's have identified a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis and demonstrated that blocking TNF signaling can prevent this fatal complication without compromising anti-tumor efficacy.
Iovance Biotherapeutics reported Q4 2025 revenue of $87 million, beating estimates, while receiving FDA fast-track designation for lifileucel in non-small cell lung cancer and reporting strong sarcoma trial data.
Moderna and Merck announced median five-year follow-up data showing intismeran autogene in combination with Keytruda reduced the risk of melanoma recurrence or death by 49% in high-risk patients following complete resection.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07564570 |
Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma |
RECRUITING | NA |
| NCT07504796 |
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab |
RECRUITING | PHASE4 |
| NCT07459543 |
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India |
NOT_YET_RECRUITING | PHASE4 |
| NCT07436390 |
IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma |
COMPLETED | NA |
| NCT07422779 |
Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia |
RECRUITING | NA |
| NCT07407166 |
Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers |
RECRUITING | NA |
| NCT07405086 |
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study |
RECRUITING | PHASE4 |
| NCT07288203 |
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07281924 |
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis |
RECRUITING | PHASE1/PHASE2 |
| NCT07237594 |
IL-17 Blockade to Decrease irAEs (REPLAY) |
NOT_YET_RECRUITING | PHASE1 |
